Clinical trials: Resolution
Filariasis
Relative Bioavailability Study of Emodepside IR-tablets and Solution
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov…
- Trial name
- NCT03383523
- Testing
- Emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
End Stage Renal Disease (ESRD)
Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)
Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD).
- Trial name
- NCT03812679
- Testing
- AMIA APD Solution Generation System
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Vantive Health LLC
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF1 (NCT00112359)
- Testing
- AZLI 75 mg three times a day (TID)
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 166 people
- Sponsor
- Gilead Sciences
Dry Eye Disease
Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease
- Trial name
- NCT04201574
- Testing
- ALY688 0.1%, ALY688 0.4%, Vehicle
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Allysta Pharmaceutical
Allergic Conjunctivitis
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01479374
- Testing
- AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2%
- Volunteers
- 397 people
- Sponsor
- Alcon Research
Dry Eye Disease
Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734210
- Testing
- 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate
- Where
- 28 sites in United States
- Volunteers
- 139 people
- Sponsor
- Surface Ophthalmics, Inc.
Healthy Volunteers
In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution
The purpose of this study is to evaluate the quality of platelets collected on the Trima Accel system after storage for 5 days in a Platelet Additive Solution (PAS), called InterSol.
- Trial name
- NCT03097289
- Testing
- Trima Accel system
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Terumo BCT
Neoplasm, Oral Mucosa
Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy
This phase I/II trial studies the safety of topical phenylephrine solution and to see how well it works in preventing oral mucosa (mouth sores) in bone marrow transplant patients receiving cyclophosphamide and total body…
- Conditions
- Neoplasm, Oral Mucosa, Transplant-Related Disorder
- Trial name
- NCT02434146
- Testing
- Topical Phenylephrine Solution
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Myopia
An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues
The purpose of this study was to assess and compare the effect of the repeated usage of 2 different care systems (one hydrogen peroxide based cleaning and disinfecting system and one PHMB containing multipurpose system) with…
- Trial name
- ID11-56 (NCT01594294)
- Testing
- AOSEPT® Plus contact lens solution, ReNu MultiPlus® contact lens solution, Etafilcon A contact lenses
- Volunteers
- 100 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Covid19
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization.
- Trial name
- NCT04662086
- Testing
- Acebilustat, Camostat
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- Stanford University
Corneal Edema
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
- Trial name
- Fuchs (NCT04498169)
- Testing
- Netarsudil Ophthalmic
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aerie Pharmaceuticals
Acute Pain
Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations
The purpose of this study is to compare the bioavailability of 25 mg DKP.TRIS given as an Enantyum® oral solution (Test formulation) and Keral® tablet (Reference formulation).
- Trial name
- NCT02209454
- Testing
- Enantyum® oral solution, Keral® tablet
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Menarini Group
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Erythematous Rosacea
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
- Trial name
- NCT00697541
- Testing
- 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Nocturnal Enuresis
Effect of Use of DryNites Absorbent Pants on the Rate of Spontaneous Resolution of Paediatric Nocturnal Enuresis (NE)
Children vary in the age at which they achieve night-time dryness; in almost all cases children will stop bed-wetting without any need for treatment.
- Trial name
- NCT04620356
- Testing
- DryNites Pyjama Pants
- Where
- 2 sites in United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Kimberly-Clark Corporation
Age-Related Macular Degeneration
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
- Trial name
- NCT02914639
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Keratosis, Actinic
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple…
- Trial name
- NCT02628236
- Testing
- Aminolevulinic Acid (ALA), BLU-U
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Dry Eye
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
The purpose of this study is to compare the efficacy and safety of HBM9036 Ophthalmic Solution versus placebo in the treatment of dry eye
- Trial name
- NCT04092907
- Testing
- HBM9036 0.25% Ophthalmic Solution
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.